PD-1 inhibitor combined with Docetaxel exerts synergistic anti-prostate cancer effect in mice by down-regulating the expression of PI3K/AKT/NFKB-P65/PD-L1 signaling pathway
CONCLUSION: Our study confirms that PD-1 inhibitors in combination with Docetaxel are a viable combination strategy and provide a safe and effective combination option for the clinical treatment of prostate cancer.PMID:38306024 | DOI:10.3233/CBM-230090 (Source: Cancer Biomarkers)
Source: Cancer Biomarkers - February 2, 2024 Category: Cancer & Oncology Authors: Sixu Zhou Baogui Wang Yingying Wei Peiru Dai Yan Chen Yingyi Xiao Hongmei Xia Chunlin Chen Weihua Yin Source Type: research
Bioinformatics analysis of markers based on m6A related to prognosis combined with immune invasion of rectal adenocarcinoma
CONCLUSION: The model has been validated as a potential prognostic biomarker for rectal cancer in multiple dimensions, aiming to provide clinicians with an indicator to assess the duration of straight adenocarcinoma. This enables early detection of rectal cancer and offers a promising target for immunotherapy.PMID:38306025 | DOI:10.3233/CBM-230123 (Source: Cancer Biomarkers)
Source: Cancer Biomarkers - February 2, 2024 Category: Cancer & Oncology Authors: Shunkang Yan Jiandong Zhang Lianghe Li Gang Chen Zhongsheng Chen Wei Zhan Source Type: research
A risk model based on lncRNA-miRNA-mRNA gene signature for predicting prognosis of patients with bladder cancer
CONCLUSIONS: The risk model based on 13 DERs patterns could well predict the prognosis for patients with BC.PMID:38306023 | DOI:10.3233/CBM-230216 (Source: Cancer Biomarkers)
Source: Cancer Biomarkers - February 2, 2024 Category: Cancer & Oncology Authors: Zhi Yi Zhao Yin Cao Hong Liang Wang Ling Yun Liu Source Type: research
PD-1 inhibitor combined with Docetaxel exerts synergistic anti-prostate cancer effect in mice by down-regulating the expression of PI3K/AKT/NFKB-P65/PD-L1 signaling pathway
CONCLUSION: Our study confirms that PD-1 inhibitors in combination with Docetaxel are a viable combination strategy and provide a safe and effective combination option for the clinical treatment of prostate cancer.PMID:38306024 | DOI:10.3233/CBM-230090 (Source: Cancer Biomarkers)
Source: Cancer Biomarkers - February 2, 2024 Category: Cancer & Oncology Authors: Sixu Zhou Baogui Wang Yingying Wei Peiru Dai Yan Chen Yingyi Xiao Hongmei Xia Chunlin Chen Weihua Yin Source Type: research
Bioinformatics analysis of markers based on m6A related to prognosis combined with immune invasion of rectal adenocarcinoma
CONCLUSION: The model has been validated as a potential prognostic biomarker for rectal cancer in multiple dimensions, aiming to provide clinicians with an indicator to assess the duration of straight adenocarcinoma. This enables early detection of rectal cancer and offers a promising target for immunotherapy.PMID:38306025 | DOI:10.3233/CBM-230123 (Source: Cancer Biomarkers)
Source: Cancer Biomarkers - February 2, 2024 Category: Cancer & Oncology Authors: Shunkang Yan Jiandong Zhang Lianghe Li Gang Chen Zhongsheng Chen Wei Zhan Source Type: research
A risk model based on lncRNA-miRNA-mRNA gene signature for predicting prognosis of patients with bladder cancer
CONCLUSIONS: The risk model based on 13 DERs patterns could well predict the prognosis for patients with BC.PMID:38306023 | DOI:10.3233/CBM-230216 (Source: Cancer Biomarkers)
Source: Cancer Biomarkers - February 2, 2024 Category: Cancer & Oncology Authors: Zhi Yi Zhao Yin Cao Hong Liang Wang Ling Yun Liu Source Type: research
PD-1 inhibitor combined with Docetaxel exerts synergistic anti-prostate cancer effect in mice by down-regulating the expression of PI3K/AKT/NFKB-P65/PD-L1 signaling pathway
CONCLUSION: Our study confirms that PD-1 inhibitors in combination with Docetaxel are a viable combination strategy and provide a safe and effective combination option for the clinical treatment of prostate cancer.PMID:38306024 | DOI:10.3233/CBM-230090 (Source: Cancer Biomarkers)
Source: Cancer Biomarkers - February 2, 2024 Category: Cancer & Oncology Authors: Sixu Zhou Baogui Wang Yingying Wei Peiru Dai Yan Chen Yingyi Xiao Hongmei Xia Chunlin Chen Weihua Yin Source Type: research
Bioinformatics analysis of markers based on m6A related to prognosis combined with immune invasion of rectal adenocarcinoma
CONCLUSION: The model has been validated as a potential prognostic biomarker for rectal cancer in multiple dimensions, aiming to provide clinicians with an indicator to assess the duration of straight adenocarcinoma. This enables early detection of rectal cancer and offers a promising target for immunotherapy.PMID:38306025 | DOI:10.3233/CBM-230123 (Source: Cancer Biomarkers)
Source: Cancer Biomarkers - February 2, 2024 Category: Cancer & Oncology Authors: Shunkang Yan Jiandong Zhang Lianghe Li Gang Chen Zhongsheng Chen Wei Zhan Source Type: research
A risk model based on lncRNA-miRNA-mRNA gene signature for predicting prognosis of patients with bladder cancer
CONCLUSIONS: The risk model based on 13 DERs patterns could well predict the prognosis for patients with BC.PMID:38306023 | DOI:10.3233/CBM-230216 (Source: Cancer Biomarkers)
Source: Cancer Biomarkers - February 2, 2024 Category: Cancer & Oncology Authors: Zhi Yi Zhao Yin Cao Hong Liang Wang Ling Yun Liu Source Type: research
PD-1 inhibitor combined with Docetaxel exerts synergistic anti-prostate cancer effect in mice by down-regulating the expression of PI3K/AKT/NFKB-P65/PD-L1 signaling pathway
CONCLUSION: Our study confirms that PD-1 inhibitors in combination with Docetaxel are a viable combination strategy and provide a safe and effective combination option for the clinical treatment of prostate cancer.PMID:38306024 | DOI:10.3233/CBM-230090 (Source: Cancer Biomarkers)
Source: Cancer Biomarkers - February 2, 2024 Category: Cancer & Oncology Authors: Sixu Zhou Baogui Wang Yingying Wei Peiru Dai Yan Chen Yingyi Xiao Hongmei Xia Chunlin Chen Weihua Yin Source Type: research
Bioinformatics analysis of markers based on m6A related to prognosis combined with immune invasion of rectal adenocarcinoma
CONCLUSION: The model has been validated as a potential prognostic biomarker for rectal cancer in multiple dimensions, aiming to provide clinicians with an indicator to assess the duration of straight adenocarcinoma. This enables early detection of rectal cancer and offers a promising target for immunotherapy.PMID:38306025 | DOI:10.3233/CBM-230123 (Source: Cancer Biomarkers)
Source: Cancer Biomarkers - February 2, 2024 Category: Cancer & Oncology Authors: Shunkang Yan Jiandong Zhang Lianghe Li Gang Chen Zhongsheng Chen Wei Zhan Source Type: research
Long non-coding RNAs PTENP1, GNG12-AS1, MAGI2-AS3 and MEG3 as tumor suppressors in breast cancer and their associations with clinicopathological parameters
CONCLUSIONS: The results suggest that the investigated lncRNAs may play important roles in breast cancer and comprise a potential factor that should be further evaluated in clinical studies.PMID:38277283 | DOI:10.3233/CBM-230259 (Source: Cancer Biomarkers)
Source: Cancer Biomarkers - January 26, 2024 Category: Cancer & Oncology Authors: Lud ěk Záveský Eva Jand áková V ít Weinberger Lubo š Minář Milada Kohoutov á Ond řej Slanař Source Type: research
Identification of TNFRSF1A as a potential biomarker for osteosarcoma
CONCLUSION: TNFRSF1A can be used to elucidate the potential relationship between the immune microenvironment and NRGs in OS pathogenesis.PMID:38250759 | DOI:10.3233/CBM-230086 (Source: Cancer Biomarkers)
Source: Cancer Biomarkers - January 22, 2024 Category: Cancer & Oncology Authors: Yuke Zhang Kai Liu Jianzhong Wang Source Type: research
EGFR, HLA-G, CD70, c-MET, and NY-ESO1 as potential biomarkers in high grade epithelial ovarian carcinoma
Cancer Biomark. 2023 Dec 28. doi: 10.3233/CBM-230200. Online ahead of print.ABSTRACTHigh grade epithelial ovarian carcinoma is an aggressive tumor. Treatment includes platinum therapy, however it recurs in most patients due to therapy resistance. In this project, we study the immunohistochemical (IHC) expression of five potential biomarkers/prognostic markers in high grade epithelial ovarian carcinoma: EGFR, HLA-G, CD70, c-MET, and NY-ESO1. A cohort of 274 patients is used. We compare the IHC expression with age, stage, ascites status, family history of cancer, disease free survival (DFS) and overall survival (OS). EGFR ex...
Source: Cancer Biomarkers - January 22, 2024 Category: Cancer & Oncology Authors: Duc Vo Yan Liu Anil K Sood Katy Rezvani Amir A Jazaeri Jinsong Liu Source Type: research
GPX4 inhibits apoptosis of thyroid cancer cells through regulating the FKBP8/Bcl-2 axis
Cancer Biomark. 2023 Dec 19. doi: 10.3233/CBM-230220. Online ahead of print.ABSTRACTGPX4 has attracted much attention as a key molecule of cell ferroptosis, but its role in cell apoptosis is rarely reported, and its role in apoptosis of thyroid cancer (TC) cell has not been reported. The analysis of TCGA database showed that both GPX4 and FKBP8 were highly expressed in TC tumor tissues; The expression of GPX4 and FKBP8 were positively correlated. The immunohistochemical analysis further confirmed that GPX4 and FKBP8 were highly expressed in TC tumor tissues. In addition, the high expression of GPX4 and FKBP8 were both sign...
Source: Cancer Biomarkers - January 22, 2024 Category: Cancer & Oncology Authors: Tianfeng Dang Jieqing Yu Yanqing Yu Junjie Jiang Yang Shi Simin Yu Congli Peng Xiang Min Yuanping Xiong Ping Long Wensheng Zhou Daofeng Dai Source Type: research
